Allogeneic hematopoietic stem cell transplantation plus donors CIK cell therapy relaped/refractory hematologic malignancy

hematology

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-11001676

Enrollment

Unknown

Registered

2011-10-29

Start date

2011-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancy

Interventions

one:allogeneic hematopoietic stem cells transplantation

Eligibility

Sex/Gender

All

Age

10 Years to 70 Years

Inclusion criteria

Inclusion criteria: patients age between 10-70, clear diagnosis hematologic malignancy, who had not reveided complete remission after two courses chemotherapy, or previous auto-hematopoietic stem cell transplantation, or relapse after standard treament.

Exclusion criteria

Exclusion criteria: organ dysfunction or failure,active infection

Design outcomes

Primary

Measure	Time frame
Survival Time;complete remission rate;GVH;	—

Countries

China

Contacts

Public ContactShi-Feng Lou

loushifeng@hotmail.com+86 13508331213

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026